Protagonist launches early-stage study of integrin antagonist for IBD

|About: Protagonist Therapeutics (PTGX)|By:, SA News Editor

Dosing is underway in a Phase 1 clinical trial evaluating Protagonist Therapeutics' (NASDAQ:PTGX) PN-10943, an oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide, for the potential treatment of inflammatory bowel disease (IBD).

The safety, tolerability, pharmacodynamic and pharmacokinetic data will inform the design of a Phase 2a study in ulcerative colitis patients that should launch in H2 2019.

Subscribe for full text news in your inbox